This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Age and combined oral contraceptive (COC) pill as a risk for cardiovascular disease

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • a combined pill containing a low dose of oestrogen (i.e. 30 mcg) is indicated in women who have migraines without auras - this is because the risk of stroke is greater the higher the dose of oestrogen in the combined pill

  • a DTB review (1) suggested that low-dose pill can also be given to women who have migraines without auras but have one additional risk factor for stroke - however the review emphasises that these patients must be followed up carefully

  • prescribing decisions, with respect to combined hormonal contraception, are made based on the UKMEC criteria below which define migraine with an aura as an absolute contraindication to combined hormonal contraception - see below for further details and guidance with respect to different migraine scenarios

UKMEC Criteria state:

Cardiovascular factors (including migraine) and UKMEC categories (3):

 

In consideration of UKMEC criteria and combined hormonal contraception (CHC):

 

 

Check the summary of product characteristics before prescribing any combined oral contraceptive pill.

Reference:

  • (1) Drug and Therapeutics Bulletin (2000), 38 (1), 1-4.
  • (2) BNF 7.3
  • (3) FSRH Clinical Guideline: Combined Hormonal Contraception (January 2019, Amended July 2019)

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.